Crossmark

Interferon alpha-induced uPAR expression on monocytes as a potential source of increased soluble uPAR in patients with SLE at high risk of developing organ damage

Crossref DOI link: https://doi.org/10.1007/s10238-025-01897-4

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wirestam, Lina https://orcid.org/0000-0003-3687-8344
Karlsson, Jesper https://orcid.org/0000-0002-7045-146X
Welin, Astrid https://orcid.org/0009-0002-0938-1535
Álvarez-Gómez, Jhonatan Antonio https://orcid.org/0000-0001-7799-294X
Wetterö, Jonas https://orcid.org/0000-0002-6916-5490
Sjöwall, Christopher https://orcid.org/0000-0003-0900-2048
Enocsson, Helena https://orcid.org/0000-0002-2125-2931
Funding

Funding for this research was provided by:

the Swedish Rheumatism Association (R-993724)

Swedish Research Council for Medicine and Health (2023-02256)

King Gustaf V’s 80-year Foundation (FAI-2022-0877)

King Gustaf V and Queen Victoria’s Freemasons’ Foundation (2022)

Ulla and Roland Gustafsson Foundation (2023-36)

Region Östergötland ALF (RÖ-981263)

Linköpings Läkaresällskap (2022)

Linköping University
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 27 June 2025

Accepted: 10 September 2025

First Online: 21 October 2025

Declarations

:

: The authors declare no competing interests.

: This study was performed in line with the principles of the Declaration of Helsinki with approvals from the Regional Ethical review board in Linköping (Decision no. Dnr M75–08/2008) for SLE and the Swedish Ethical Review Authority (Decision no. 2023-03937-01) for HBD.

: Oral and written informed consents were obtained from all patients.

Document is current

Any future updates will be listed below